What is Zacks Research’s Estimate for PBH Q1 Earnings?

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Zacks Research lifted their Q1 2027 earnings estimates for Prestige Consumer Healthcare in a report issued on Tuesday, April 22nd. Zacks Research analyst R. Department now forecasts that the company will earn $1.11 per share for the quarter, up from their previous estimate of $1.09. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share.

Other analysts have also recently issued reports about the company. Oppenheimer upped their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research report on Thursday, February 13th. StockNews.com lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, April 8th. Canaccord Genuity Group lifted their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. DA Davidson increased their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, Royal Bank of Canada lifted their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a “sector perform” rating in a research note on Friday, March 21st. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and a consensus price target of $93.33.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $80.52 on Friday. The company has a market capitalization of $3.99 billion, a price-to-earnings ratio of 18.86, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47. Prestige Consumer Healthcare has a 52-week low of $62.35 and a 52-week high of $90.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The stock has a 50 day moving average price of $83.60 and a 200 day moving average price of $80.56.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%.

Insider Activity

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the sale, the senior vice president now owns 17,157 shares in the company, valued at $1,544,130. This represents a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.60% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Kestra Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth about $27,000. CIBC Private Wealth Group LLC grew its position in Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock worth $34,000 after purchasing an additional 152 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of Prestige Consumer Healthcare in the first quarter valued at approximately $38,000. Headlands Technologies LLC bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $40,000. Finally, McIlrath & Eck LLC boosted its position in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock worth $75,000 after buying an additional 154 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.